BeOne Medicines AG's stock rose by 6.01% and reached a 20-day high, reflecting positive investor sentiment amid broader market gains, with the Nasdaq-100 up 0.65% and the S&P 500 up 0.49%.
The surge is attributed to the company's announcement regarding the ZIIHERA trial results, which demonstrated significant improvements in overall survival for patients with HER2+ gastroesophageal adenocarcinoma. The trial showed a median overall survival of 26.4 months, marking a 28% reduction in the risk of death compared to the control group, thus highlighting the potential of ZIIHERA in treatment.
These promising results not only enhance BeOne's position in the oncology market but also suggest a potential expansion of treatment access in the Asia-Pacific region, addressing a critical need for effective therapies. Investors are likely to remain optimistic as the company moves forward with its plans.
Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is 403.76 USD with a low forecast of 385.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is 403.76 USD with a low forecast of 385.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 350.000
Low
385.00
Averages
403.76
High
424.00
Current: 350.000
Low
385.00
Averages
403.76
High
424.00
Morgan Stanley
Overweight
maintain
$390 -> $405
2026-01-08
Reason
Morgan Stanley
Price Target
$390 -> $405
AI Analysis
2026-01-08
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on BeOne Medicines to $405 from $390 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Truist
Buy
initiated
$400
2025-11-24
Reason
Truist
Price Target
$400
2025-11-24
initiated
Buy
Reason
Truist initiated coverage of BeOne Medicines with a Buy rating and $400 price target. The firm expect Brukinsa's revenue stream to sustainably support the company's operations and drive BeOne Medicines toward the guided positive free cash flow by 2025, the analyst tells investors in a research note. The company's leadership position in CLL - chronic lymphocytic leukemia - is well-solidified by Brukinsa's differentiation and the franchise's comprehensive growth strategy, including proprietary next-wave assets such as sonrotoclax and BTK CDAC, Truist added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ONC
Unlock Now
RBC Capital
Outperform
maintain
$395 -> $408
2025-11-18
Reason
RBC Capital
Price Target
$395 -> $408
2025-11-18
maintain
Outperform
Reason
RBC Capital raised the firm's price target on BeOne Medicines to $408 from $395 and keeps an Outperform rating on the shares. The Ziihera phase III HORIZON-GEA update clears the way for a potential 1L approval in combination with Tevimbra and chemotherapy and adds incremental upside to shares, the analyst tells investors in a research note.
Morgan Stanley
Sean Laaman
Overweight
maintain
$185 -> $205
2025-11-17
Reason
Morgan Stanley
Sean Laaman
Price Target
$185 -> $205
2025-11-17
maintain
Overweight
Reason
Morgan Stanley analyst Sean Laaman raised the firm's price target on Jazz Pharmaceuticals (JAZZ) to $205 from $185 and keeps an Overweight rating on the shares. Jazz reported positive topline results for the HERIZON-GEA-01 trial evaluating Ziihera, a bispecific HER2-directed antibody, in combination with chemotherapy, with or without BeOne Medicine's (ONC) PD-1 inhibitor Tevimbra, as first-line treatment for HER2-positive locally advanced or metastatic GEA, but and while limited details were provided, Jazz indicated a highly competitive profile ahead of the sBLA submission in 1H26, the analyst tells investors in a research note. Ziihera plus chemotherapy and Ziihera plus tislelizumab and chemotherapy demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival compared to the control arm, positioning Ziihera as a potential new standard of care for first-line HER2-positive GEA, replacing trastuzumab in this setting, the firm says.
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
